{"id":"NCT02234583","sponsor":"Daiichi Sankyo","briefTitle":"An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia","officialTitle":"An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-04","primaryCompletion":"2017-04-19","completion":"2017-04-19","firstPosted":"2014-09-09","resultsPosted":"2020-07-23","lastUpdate":"2020-07-23"},"enrollment":2485,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pain Associated With Fibromyalgia"],"interventions":[{"type":"DRUG","name":"DS-5565","otherNames":["Investigational product"]}],"arms":[{"label":"DS-5565","type":"EXPERIMENTAL"}],"summary":"This is an open-label study of DS-5565 in subjects who either completed participation in a preceding Phase 3 study of DS-5565 in fibromyalgia (FM); i.e. DS5565-A-E309 (NCT02146430), DS5565-A-E310 (NCT02187471), or DS5565-A-E311 (NCT02187159) or are de novo subjects. Eligible subjects will be assigned to receive open-label DS-5565 for 52 weeks. All subjects will receive DS-5565 15 mg once daily (QD) for the first three weeks of the treatment period. After three weeks, subjects may be titrated to 15 mg twice daily (BID) based on protocol-specified criteria.","primaryOutcome":{"measure":"Average Daily Pain Score (ADPS) for DS-5565","timeFrame":"Day 0 (baseline) up to to Week 52 postdose","effectByArm":[{"arm":"Rollover DS-5565 15 mg QD Modal","deltaMin":4.77,"sd":2.23},{"arm":"Rollover DS-5565 15 mg BID Modal","deltaMin":5.58,"sd":2.22},{"arm":"De Novo DS-5565 15 mg QD Modal","deltaMin":7.08,"sd":1.4},{"arm":"De Novo DS-5565 15 mg BID Modal","deltaMin":7.38,"sd":1.37}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":15},"locations":{"siteCount":276,"countries":["United States","Australia","Austria","Bulgaria","Canada","Chile","Czechia","Denmark","Estonia","Finland","France","Germany","Hungary","Latvia","Lithuania","New Zealand","Norway","Poland","Portugal","Puerto Rico","Romania","Russia","Serbia","Slovakia","Slovenia","South Africa","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["31284771"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":41,"n":847},"commonTop":["Weight increased","Dizziness","Headache","Somnolence","Drug withdrawal syndrome"]}}